Novel, selective ATP-competitive inhibitor of Aurora B kinase in vitro
values are 50, 250 and 1000 nM for Aurora B, C and A kinases respectively). Selective over a range of other kinases including cdk1 and PLK1 (IC50
> 10 μ
M). Inhibits cell division and displays selective toxicity towards proliferating tumor cells versus non-dividing cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold with the permission of AstraZeneca UK Ltd.
Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores.
Ditchfield et al.
J.Cell Biol., 2003;161:267
Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.
Jung et al.
Validating Aurora B as an anti-cancer drug target.
Girdler et al.
J.Cell Sci., 2006;119:3664
The citations listed below are publications that use Tocris products. Selected citations for ZM 447439 include:
Showing Results 1 - 10 of 25